Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

1145 - Excellent response of nivolumab in patient with metastatic malignant melanoma of vagina: a case report

Date

24 Nov 2018

Session

Poster display - Cocktail

Presenters

Aungsumal Maisrikrod

Authors

A. Maisrikrod1, A. Dechaphunkul2

Author affiliations

  • 1 Medicine, Division Of Medical Oncology, Songklanagarind Hospital, 90110 - Hat Yai/TH
  • 2 Medicine, Division Of Medical Oncology, Prince of Songkla University, 90110 - Hat-Yai/TH
More

Resources

Abstract 1145

Case Summary

A 71-year old lady has been diagnosed with unresectable malignant melanoma of vagina since June 2017. At that time, she received high dose rate brachytherapy (7 Gy) followed by intracavitary radiotherapy (RT). Follow up MRI showed partial response of disease with residual tumor at vagina. Three months after completion of RT, she developed obstructive uropathy with acute kidney injury (Cr 3.99 mg%). Therefore, percutaneous nephrostomy (PCN) of the right ureter was performed with good recovery of renal function (Cr 0.98 mg%). The subsequent CT scan of chest and whole abdomen revealed local recurrence of vaginal mass with multiple liver and iliac nodes metastasis. She therefore was referred to us for seeking opinion regarding systemic therapy for metastatic malignant melanoma of vagina. The patient received nivolumab 200 mg (3 mg/kg) IV q 2 weeks with good tolerability. There was no immune-related adverse event occurred. After 4 cycles of nivolumab, the patient reported no more urine passing through PCN, and she was able to pass urine through the urethra. Subsequently, the PCN was successfully removed. Follow up CT scan after 4 cycles of nivolumab showed partial response (38% reduction). She hence continued 4 more cycles of nivolumab, and CT scan still showed further reduction of tumor (53% reduction). Here, we present the excellent response of anti-PD-1 immunotherapy in patient with uncommon site of malignant melanoma.

Editorial acknowledgement

Clinical trial identification

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.